Dear Editor, Recent failures to improve the prognostic of sepsis have underlined the need for a better phenotypical description of septic subjects. In this view, endocan, an endothelial proteoglycan secreted under proinflammatory conditions, has been described as a useful biomarker to early identify patients at higher risk of poor outcomes during the time course of sepsis [1] . More recently, a major catabolite of endocan, p14, has been observed at high plasmatic levels in a series of septic subjects, paving the way for a more accurate prediction of poor outcomes in such patients. However, major variations of p14 were observed between patients in this series, with unknown clinical significance [2] . Furthermore, it is currently unknown whether p14 could undergo renal elimination.
We performed a post hoc analysis based on the data from a previously published prospective cohort of severe septic patients [3] . Ninety-nine patients underwent measurement of p14 on EDTA plasma. Plasmatic endocan cleavage ratio (ECR) was calculated as plasma p14/(endocan + p14) ratio (endocan and p14 being expressed in pmol/mL) on baseline and 24 h, 48 h, and 72 h following ICU admission. Baseline characteristics of patients are exposed in Additional file 1.
In this cohort, ECR on enrolment was correlated with baseline SAPS 2 (ρ = 0.36, 95% CI (0.17-0.53); p < 10 (Table 1) . Over 72 h, patients with a baseline renal SOFA at 4 had higher median plasmatic ECR than those with baseline renal SOFA < 4 (p < 10 − 3 ) (Fig. 1) .
Our results suggest that circulating concentrations of p14 might be influenced by the severity of acute renal failure. Therefore, it could be proposed that, by contrast with endocan, p14 could be eliminated through glomerular filtration, thus suggesting that it should be measured in urine rather that in blood. This discrepancy might be explained by the smaller molecular weight of p14, as well as the absence of polyanionic glycanic chain on its protein core. Further explorations are needed to confirm these hypotheses. 
